BridgeMD
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function
EU CTIS ID: 2023-508162-15-00
What this study is testing
To determine whether balcinrenone/dapagliflozin is superior to dapagliflozin in reducing the risk of CV death and HF events with and without hospitalisation
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Age ≥ 18 years
- 2. Documented diagnosis of symptomatic HF (NYHA functional class II-IV)
- 3. Having had a recent HF event within 6 months (hospitalization or urgent visit)
- 4. Have a LVEF value from an assessment within the last 12 months
- 5. Managed with SoC therapy for HF and renal impairment according to local guidelines
- 6. NT-proBNP must be >300 pg/mL (>600 pg/mL if concomitant atrial fibrillation or atrial flutter)
You likely can't join if
- 1. Acute coronary syndrome (unstable angina or myocardial infarction), stroke or transient ischaemic attack within the previous 3 months prior to enrolment or during the screening period
- 8. Type 1 diabetes mellitus
- 9. Kidney replacement therapy in the past 4 weeks, currently requiring kidney replacement or imminent plan to start kidney replacement therapy
- 12. Treatment with strong or moderate CYP3A4 inhibitor or inducer
- 10. Acute or chronic liver disease with severe impairment of liver function, eg, ascites, oesophageal varices, coagulopathy, and encephalopathy
- 11. Suspected or confirmed COVID-19 infection within the last 4 weeks or hospitalisation for COVID-19 within the last 12 weeks
See the full eligibility criteria
- 1. Age ≥ 18 years
- 2. Documented diagnosis of symptomatic HF (NYHA functional class II-IV)
- 3. Having had a recent HF event within 6 months (hospitalization or urgent visit)
- 4. Have a LVEF value from an assessment within the last 12 months
- 5. Managed with SoC therapy for HF and renal impairment according to local guidelines
- 6. NT-proBNP must be >300 pg/mL (>600 pg/mL if concomitant atrial fibrillation or atrial flutter)
- 7. Not taking an MRA
- 8. An eGFR ≥ 20 to < 60 mL/min/1.73 m2
- 9. Serum/plasma potassium ≤ 5.0 mmol/L
- 1. Acute coronary syndrome (unstable angina or myocardial infarction), stroke or transient ischaemic attack within the previous 3 months prior to enrolment or during the screening period
- 8. Type 1 diabetes mellitus
- 9. Kidney replacement therapy in the past 4 weeks, currently requiring kidney replacement or imminent plan to start kidney replacement therapy
- 12. Treatment with strong or moderate CYP3A4 inhibitor or inducer
- 10. Acute or chronic liver disease with severe impairment of liver function, eg, ascites, oesophageal varices, coagulopathy, and encephalopathy
- 11. Suspected or confirmed COVID-19 infection within the last 4 weeks or hospitalisation for COVID-19 within the last 12 weeks
- 2. Major cardiac surgery, coronary revascularisation or valvular repair or replacement, or implantation of a Cardiac resynchronisation therapy device within 3 months prior to enrolment or planned to undergo any of these operations
- 3. History of hypertrophic obstructive cardiomyopathy
- 4. Complex congenital heart disease or severe uncorrected primary valvular disease
- 5. Symptomatic bradycardia or second- or third-degree heart block without a pacemaker
- 6. Systolic BP < 90 mmHg, or symptomatic hypotension within the past 24 hours
- 7. Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD or exacerbation of COPD requiring invasive mechanical ventilation assistance within 12 months prior to enrolment
The study team makes the final eligibility decision.
Where it's taking place
- Turkey
- Vietnam
- Taiwan
- Ukraine
- Thailand
- Australia
- Mexico
- Peru
- Malaysia
- Japan
- China
- Colombia
- Philippines
- South Africa
- United Kingdom
- Argentina
- Canada
- India
- United States
- Saudi Arabia
+ 4 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Turkey; Vietnam; Taiwan; Ukraine; Thailand; Australia and 18 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.